Background: Recent literature highlights the importance of germline genetic testing in prostate cancer (PCa) patients. Surprisingly, a literature review indicates that family history (FH) records are incomplete in the major published studies from prostate cancer patients.
Methods: Prospective family history data were gathered from 496 men in a single institution with a personal history of PCa who underwent germline genetic testing using a panel of at least 79 genes. Comprehensive first degree FH were obtained in all PCa of patients and analysis of prevalent FH was assessed at the time of sample collection.
Results: Pathogenic/likely pathogenic variants (PV/LPVs) were not associated with age at diagnosis, race, or presence of metastasis. One or more first degree relatives (FDR) with any cancer was not predictive for germline PV/LPVs for men with PCa (p = .96). Separate analysis of patients with one or more FDR with breast, prostate, ovarian, or pancreatic cancer revealed that only FDR with breast or ovarian cancer was predictive for PV/LPVs (p = .028, p = .015 respectively). Patients with a FDR with breast cancer had 1.8 increased risk of PV/LPVs, and patients with a FDR with ovarian cancer had 2.9 increased risk of PV/LPV.
Conclusion: In men with a personal history of PCa, germline PV/LPVs were associated with a FDR with breast or ovarian cancer. Notably having FDRs with PCa does not predict for PV/LPVs. These data emphasize the contribution of FH in a data set with complete ascertainment of FH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pros.24120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer Models.
Cancers (Basel)
December 2024
Translational Oncology Research Center (TORC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar.
Background: Chemoresistance in triple-negative breast cancer (TNBC) presents a significant clinical hurdle, limiting the efficacy of treatments like doxorubicin. This study aimed to explore the molecular changes associated with doxorubicin resistance and identify potential therapeutic targets to overcome this resistance, thereby improving treatment outcomes for TNBC patients.
Methods: Doxorubicin-resistant (DoxR) TNBC models (MDA-MB-231 and BT-549) were generated by exposing cells to increasing concentrations of doxorubicin.
Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2- Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia.
Breast J
January 2025
Department of Oncology University Hospital Center Split School of Medicine University of Split, Split, Croatia.
Article Synopsis
- The study focuses on the challenges of managing disease recurrence in early-stage hormone receptor-positive (HR+), HER2-negative breast cancer due to its biological complexity and the presence of PIK3CA mutations.
- Approximately 30-40% of advanced HR+/HER2- breast cancer patients have PIK3CA mutations, which are linked to poor prognosis by activating pathways that promote cell growth.
- The research found that patients with the PIK3CA mutation, particularly the H1047 variant, had a lower risk of disease recurrence compared to those without the mutation, suggesting its potential as a biomarker for personalized treatment strategies.
Gestational Diabetes, the Human Milk Metabolome, and Infant Growth and Adiposity.
JAMA Netw Open
December 2024
Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.
Importance: Gestational diabetes (GD) is linked to health risks for the birthing parent and infant. The outcomes of GD on human milk composition are mostly unknown.
Objective: To determine associations between GD, the human milk metabolome, and infant growth and body composition.
Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
Int J Cancer
December 2024
Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, One Medical Center Drive, Lebanon, New Hampshire, USA.
Article Synopsis
- Triple-negative breast cancer (TNBC) is a highly aggressive subtype with varied characteristics, limited treatment choices, and poor clinical outcomes, particularly when associated with homologous recombination deficiency (HRD).
- The study analyzed TNBC tumors from two groups (n=32 and n=58), revealing significant differences in genome-wide copy number and methylation alterations linked to HRD, including lower methylation in specific genomic regions.
- Findings indicate that HRD in TNBC is associated with key biological pathways, and using machine learning can aid in classifying tumors based on HRD and methylation patterns, offering potential for improved treatment strategies.
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1.
Mol Carcinog
January 2025
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Malignant peripheral nerve sheath tumors (MPNSTs) show altered DNA methylation patterns, suggesting these changes could be used as specific biomarkers for NF1 patient screening.
- Researchers conducted a study involving DNA methylation profiling from tumor and adjacent tissue samples of 13 MPNST patients, finding 73 candidate CpGs that could distinguish MPNSTs from neurofibromas.
- Five validated biomarkers demonstrated high sensitivity and specificity in tissue detection, and higher methylation levels were observed in plasma tests, indicating potential for early detection of MPNST in NF1 patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!